Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer

IMPORTANCE: Treatment with nivolumab-ipilimumab combination therapy was found to improve overall survival compared with chemotherapy among patients with advanced non–small cell lung cancer (NSCLC) in the CheckMate 227 clinical trial. However, these drugs are substantially more expensive than chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Courtney, P. Travis, Yip, Anthony T., Cherry, Daniel R., Salans, Mia A., Kumar, Abhishek, Murphy, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094011/
https://www.ncbi.nlm.nih.gov/pubmed/33938936
http://dx.doi.org/10.1001/jamanetworkopen.2021.8787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094011/
https://www.ncbi.nlm.nih.gov/pubmed/33938936
http://dx.doi.org/10.1001/jamanetworkopen.2021.8787

Ejemplares similares